More people died from other respiratory problems than from Covid in 2020. Inbentus has the intention of democratising medical technology by developing low-cost respirators. The company is ready to commercialise its first respirator internationally and is developing the second piece of ICU equipment to cover some of the foreseen global demand of $12bn in 2027.
Thousands of people die every day from a lack of medical respirators. These high-reliability devices are inaccessible to emerging markets due to their expense. COVID has made this problem worse.
Established at the beginning of 2020, we want to make respirators more accessible to less affluent populations. That's why we started INBENTUS.
In less than 1 month we've developed a COVID emergency respirator prototype that's competitively priced with the first units having been delivered to Latin American countries already.
Although our initial strategy is focused on COVID patients, several international studies indicate that respiratory pathologies will be a huge global problem over the next 20 years, due to:
- Increases in world population by almost 30%.
- Increases in life expectancy.
By 2027, €12bn+ euros are expected to be spent on respiratory medical technology which has sustained annual growth of 16%.
To meet this strong demand, we plan to start developing a new & improved high-performance respirator that's more inexpensive with the aim to achieve high penetration in Latin America & Africa in the coming years. Hospitals of public & private health networks are our main targets to obtain revenue.
Funds will be used to boost sales and complete authorization of our existing respirator, launch local campaigns in target countries and to develop our new, high-performance respirator product.